MedTrace Logo

Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients

NCT06897605 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-04-02

No results posted yet for this study

Summary

Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, primarily used in the management of type 2 diabetes mellitus. Emerging research suggests that SGLT2 inhibitors may offer additional benefits, including reducing the risk of cardiovascular events and renal complications. Post hoc analyses of previous clinical trials have shown that patients treated with SGLT2 inhibitors exhibited higher levels of hemoglobin and hematocrit compared to those in the control group. These findings suggest that dapagliflozin's ability to elevate hemoglobin levels could potentially be utilized for the treatment of anemia in patients with chronic kidney disease.

Conditions

  • Chronic Kidney Disease(CKD)
  • Anemia, Kidney Disease, Chronic

Interventions

DRUG

Dapagliflozin (DAPA)

Dapagliflizin 10 mg tablets once daily for 12 weeks

DRUG

Erythropoiesis Stimulating Agent

Erythropoiesis stimulating agent (ESA) therapy

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Principal Investigators

  • Noha O. Mansour, Ph.D. · Mansoura University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-01
Primary Completion
2025-10-31
Completion
2025-10-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06897605 on ClinicalTrials.gov